[ad_1]
A Covid-19 vaccine project supported by GlaxoSmithKline Plc is heading for advanced trials after showing strong immune response in early studies.
Sichuan Clover Biopharmaceuticals Inc. of China said its injection induced neutralizing antibodies and was found to be safe in a study involving 150 adults and elderly volunteers. The vaccine uses adjuvants – agents that stimulate the response of a vaccine – from Glaxo and Dynavax Technologies Corp.
Covid-19 Vaccinations are about to start
Advanced-stage trials using Glaxo’s adjuvant are expected to begin this month, while studies using the Dynavax system will begin in the first half of 2021, according to a statement Friday.
The experimental vaccine is one of dozens of projects around the world that are in early testing, behind those of Pfizer Inc., Moderna Inc. and AstraZeneca Plc. They are moving forward with their plans based on the hope that the world will need multiple injections to defeat the pathogen.
The Clover vaccine has shown long term stability at refrigerator temperature. This would allow it to be widely used, including in developing countries, said Richard Hatchett, head of the Coalition for Epidemic Preparedness Innovations, in the statement.
One of the goals is to make hundreds of millions of doses of the vaccine accessible globally through the Covax initiative, which aims to deploy injections fairly, Hatchett said.
Glaxo shares rose 1.6% at the start of trading in London.
[ad_2]
Source link